MedTrace Logo

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

NCT00453440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1502

Last updated 2017-09-12

No results posted yet for this study

Summary

This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.

The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin.

They will be asked to give two samples to test for the presence of the genetic marker HLA-B\*5701. The two samples are:

* A cheek swab
* A blood sample

In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B\*5701 testing.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

PROCEDURE

Cheek swab & blood test

Cheek swab \& blood test

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-20
Primary Completion
2007-08-10
Completion
2007-08-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00453440 on ClinicalTrials.gov